Diligence memo · auto-generated · as of July 2, 2026
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Transposon Therapeutics, Inc. operates in Pharmaceuticals, based in San Diego.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Transposon Therapeutics, Inc. has raised $59M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2020-11-25.
Most recent recorded round closed around 2024-07-10.
Valuation (modeled)modeled
Provath models Transposon Therapeutics, Inc. at approximately $41M (range $15M–$62M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.07× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 24 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 4.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 39% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.